#Preventativemedicine

A groundbreaking study recently published in the Mayo Clinic Proceedings has unveiled a potential new “gold standard” in cholesterol treatment, which could prevent over 330,000 deaths annually caused by cardiovascular diseases. Spearheaded by an international team led by Professor Maciej Banach from the John Paul II Catholic University in Lublin, this research represents the largest meta-analysis to date examining the efficacy of cholesterol-lowering treatments for those at high risk of heart attacks and strokes. The study found that combining statins with ezetimibe, instead of using statins alone, significantly lowers “bad” LDL cholesterol and reduces mortality from cardiovascular diseases.

A major meta-analysis published in a leading medical journal signals a potential new standard in cholesterol care. International researchers, led by a professor from a Polish university, analyzed data from 14 trials involving more than 100,000 high-risk patients. The study found that adding ezetimibe to statin therapy lowers LDL cholesterol more effectively than statins alone and reduces deaths from cardiovascular disease.

For Thai readers, the findings are highly relevant because cardiovascular disease remains a top health challenge in Thailand. The research reports a 19% decrease in all-cause mortality and a 16% drop in cardiovascular deaths when ezetimibe is added to statins. Major cardiovascular events also fell by 18%, underscoring the potential to save lives and reduce economic burdens from heart disease.